[ad_1]
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Torrent Pharmaceuticals Ltd. has Rs 70 billion (75% of total sales; including Curatio Healthcare Pvt. Ltd.) worth of highly profitable branded formulation sales spread across India, Brazil and rest of world markets.
In the near term, Curatio acquisition will increase Torrent Pharma’s net debt and we see this acquisition as earning per share dilutive. Post factoring in Curatio acquisition, our EPS for FY23 and FY24 stands reduced by ~5%.
However, the deal is a strategic fit for the company, given that it gives presence in high growing cosmetic derma segment and can enhance profitability of Curatio portfolio with cost synergies, geographical expansion and price hike as well as accelerate the topline growth.
Historically Torrent Pharma have managed to integrate successfully Unichem and Elder acquisition which gives us comfort.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
[ad_2]
Image and article originally from www.bqprime.com. Read the original article here.